Concerns on generic enoxaparin use in acute coronary syndrome;Consideraciones sobre el uso de enoxaparina genérica en SCA

Arquivos Brasileiros de Cardiologia

Volumn 95, Issue 4, 2010, Pages 551-552

  Gomes, Marise ^a   Ramacciotti, Eduardo ^a   Litinas, Evangelos ^a   Fareed, Jawed ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; HUMAN; LETTER; ACUTE CORONARY SYNDROME; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; METHODOLOGY; SOUTH AMERICA;

ANTICOAGULANT AGENT; ENOXAPARIN; GENERIC DRUG;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUGS, GENERIC; ENOXAPARIN; HUMANS; SOUTH AMERICA;

EID: 78650729091     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/s0066-782x2010001400022     Document Type: Letter

References (8)

1. Gray E, Mulloy B. Biosimilar low molecular weight heparin products. J Thromb Haemost. 2009;7(7):1218-21.
2. Maddineni J, Walenga JM, Jeske W P, Hoppensteadt DA, Fareed J, Wahi R, et al. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Clin Appl Thromb Hemost. 2006;12(3):267-76.
3. Fareed J, Ma Q, Florian M, Maddineni J, Iqbal O, Hoppensteadt DA, et al. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis. Semin Thromb Hemost. 2004;30(Suppl 1):89-104.
4. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006;152(6):1042-50.
5. Rosito GA, da Silva OB, Ribeiro J P. Evidências farmacológico-clínicas para o uso das heparinas de baixo peso molecular nas síndromes coronarianas agudas. Arq Bras Cardiol. 2001;77(2):184-9.
6. Nicolau JC, Cohen M, Montalescot G. Differences among low-molecularweight heparins: evidence in patients with acute coronary syndromes. J Cardiovasc Pharmacol. 2009;53(6):440-5.
7. Fareed J, Leong W, Hoppensteadt DA, Jeske W P, Walenga J, Bick RL. Development of generic low molecular weight heparins: a perspective. Hematol Oncol Clin North Am. 2005;19(1):53-68, v-vi. (Pubitemid 40522265)
8. Gomes M. Análise comparativa da segurança e eficácia da enoxaparina genérica versus enoxaparina padrão, na profilaxia da doença tromboembólica venosa em pacientes submetidos a operação maior abdominal [Tese]. São Paulo: Escola Paulista de Medicina. Universidade Federal de São Paulo; 2009.